Editorial
Expanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.7844 ↗At a glance
Editorial in Journal of Drugs in Dermatology, 2024. Written by Nicole E Chin and 1 co-authors. Major MEDLINE topics: Tranexamic Acid, Melanosis. Cited 1 times so far (Crossref).
Abstract (original language)
Tranexamic acid (TXA) is an antifibrinolytic medication largely known for its efficacy in managing menorrhagia, or heavy periods, making it a medication predominantly used by women.
Subjects
MeSH terms (MEDLINE)
Tranexamic AcidMelanosisMaleHumansAdministration, CutaneousTreatment Outcome
Substances
Tranexamic Acid
Cite
APA
Chin, N. E., & Austin, A. H. (2024). Expanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7844
Vancouver
Chin NE, Austin AH. Expanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7844
BibTeX
@article{Chin2024,
author = {Chin, Nicole E and Austin, Andrea Hui},
title = {Expanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.7844}
}
EUVIMED